Nektar Therapeutics (NKTR) came out with a quarterly loss of $1.85 per share versus the Zacks Consensus Estimate of a loss of $2.85. This compares to a loss of $2.7 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +35.09%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $3.13 per share when it actually produced a loss of $2.95, delivering a surprise of +5.75%.Over the last four quarters, ...